By now you have probably heard of The Chainsmokers, and can even hum at least a few of their tunes from memory. Their melodies are the sort that can get stuck even in the heads of those that usually do not share a full appreciation for electronic dance music. Luckily, even the most stubborn to accept change are starting to come around, thanks to artists like those included on Forbes Magazine’s 2018 World’s Highest-Paid DJs list. The Chainsmokers have steadily climbed this chart over the past few years, reaching No.31 on the latest collection of most financially successful artists.
One of the most astonishing accomplishments for this duo from New York is their acquiring of their three year DJ residency in Las Vegas. There they play nightly while bringing in nearly a half a million dollars every time they grace the stage. If you’ve really listened, you’ve probably noticed that their attention to detail is what truly sets them apart from the rest, securing their place among some of the biggest names to enter the EDM game. Veterans like Carl Cox have been caught numerous times commenting on how they have served as an inspiration to even himself.
It may seem that The Chainsmokers owe a bit of their fame to their unique use of custom-designed synthesizer patches and perfectly timing their business attack. Although many EDM artists have fallen out of the adoration from the masses, the same cannot be true when it comes to this iconic duo. Whether it is the perfect BPM, unconventional time signatures, or just a stroke of excellent luck, The Chainsmokers have proven to the world that they have what it takes to continually shape the EDM underground long after the commercial exploitation of the sub culture’s origins by endless copycats.
When all is said and done, The Chainsmokers will still be adored by countless old school ravers and EDM newcomers for many decades to follow. Next time you hear their song on a television commercial, just imagine how much they are making off of that 30 second licensing of their music for an advertisement.
Marc Beer, the current CEO of Renovia Inc., has developed a reputation of transforming startups into commercial enterprises with strong financial muscles to achieve their strategic needs. The recent obtaining of a total of $42 million for the biotechnology startup he co-founded has outlined this reputation. The funds, raised mainly through venture debt and Series B funding, will be used to finance the research and development of diagnostic technologies for testing urinary incontinence, a medical condition affecting close to 250 million women globally. The funds will also be used in developing affordable drugs for the medical condition that affects the muscles of the pelvic floor. Learn more: https://renoviainc.com/
The funds were raised through an infusion approach that saw the company receive funds from different investment companies such as the Longwood Fund, Ascension Ventures and Perceptive Advisers. The funds will be used in further developing Revia, a drug for treating pelvic floor disorder which was developed by Revia, Inc. and has already been approved by the FDA. According to Marc Beer, the new round of funding will help the company perfect the diagnostic systems for the medical condition by merging innovative patient-based proprietary technologies with value data harnessed through digital health platforms and technologies. It is this merger that Marc Beer hopes will lead to reduced overhead cost for diagnosing and treating urinary incontinence.
A Business Originator Par Excellence
Marc Beer is a business generator with a unique capability of transforming startups into profitable commercial enterprises. In 2016, he brought together a group of leading venture capital funds specializing in the healthcare industry to found Revia, Inc. through visionary leadership. He has guided the company to significant including initiating a new round of funding and development of a drug that has already been approved by the FDA. In 2000, he successfully founded a biotechnology firm, ViaCell and served as its CEO. The startup focused on umbilical cord stem cell research; an untapped area of research that soon thrust the company into the limelight and operational success. Under Marc Beer’s leadership, the company was listed in the NASDAQ while its employee base grew tremendously within seven short years of its founding. The success soon attracted the interests of big corporations including PerkinElmer which acquired it in 2007. Following the acquisition of ViaCell, he joined Erytech Pharma as a board member. He also founded Good Start Genetics, Inc. and cofounded Minerva Neurosciences where he served as a board member and chairman.
Academic and Professional Background
Marc Beer is an accomplished business developer with vast experience not only the pharmaceutical industry. He has also worked in the sales and marketing industry. Before venturing into startup origination and entrepreneurship, he was Genzyme’s vice president in charge of global marketing docket. He holds a Bachelor of Science degree from Miami University where he majored in business studies.
Economists are people associated with high expertise in the intricacies of economics. This involves proposing, creation and implementation of policies that serve in the private sector and public sector, the government. Economists interpret and predict market trends, which is majorly applied in the stock exchange market. They carry out research to determine and come up with solutions to economic problems in line with production and distribution of goods and services. They also study socioeconomic effects of new and upcoming public policies involving proposed legislations, taxes, services, regulations and red tapes. Of such people is ireport.CNN’s Christian Broda, a former professor at the University Of Chicago Booth School Of Business, the current managing director of Duquesne Capital Management.
Christian Broda obtained his Ph.D. from the Massachusetts Institute Technology and a bachelor’s degree in business economics from Universidad de San Andres. Mr. Broda worked as Chief International Economist I Barclays Bank and as Head of international research in Lehman Brothers; he is undoubtedly experienced in matters pertaining to economics attributed to his several job experiences. His talents lie in Hedge Fund management, alternative funds, portfolio management, fixed income, equity, capital markets and investments. He was also a member of the editorial board of the IMF Economic Review and the James Skemper Foundation Scholar (2006-2008). He is an active writer following his several annual and quarterly articles based on economics and numerous other publications.
Most economists work extra hard to come up with updated theories that play a great role in molding and developing the society and all the people involved. This leads to the conception of great ideas and innovations if carefully and professionally put into perspective. Economists also play an enormous role in shaping the future and fate of a country’s economy; the decisions they make can either build or destroy the economy for instance with the influence of fluctuating prices and dropping of currency strength. Fortunately to date great economists like Christian Broda, against heavy criticism have played part in success of the economic society as leaders and determinants to the economy, for instance, the maintenance of the dollar strength in the U.S. economy. Christian’s prediction on the strengthening of the dollar in 2009 surely came to pass as seen in the U.S. monetary and fiscal policy.
Economists are also obligated to carry out research in the international finance and trade and present it in models of prediction of the next market trends as influenced by changing people’s wants, currency strengths and changing technology. They then advise businesses, other organizations and mainly the government agencies on aspects of economic and social policies, for instance, taxation, interest rates and employment levels. They also study how exchange rates affect competition and production in the market and with this knowledge make policies and decision on how to ascertain positive economic projections.